Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemiaStephen K. Tahir, Darren C. Phillips, Morey L. Smith et al.|Blood|2023Cited by 30
Current Progress and Emerging Role of Essential Oils in Drug Delivery TherapeuticsRokeya Sultana, Md. Faiyazuddin, Sourav Mohanto et al.|Current Drug Delivery|2024Cited by 13
First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)Maja J.A. de Jonge, Víctor Moreno, Benedito A. Carneiro et al.|Blood|2019Cited by 11
AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell LymphomaMojca Jongen‐Lavrencic, Daniel Morillo, Junichiro Yuda et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2
Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.Monica Motwani, Patricia LoRusso, Dimple Modi et al.|Journal of Clinical Oncology|2020Cited by 0